VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
PR Newswire —
HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be...